Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CAVA Group Inc (CAVA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

CAVA Group IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

CAVA Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? CAVA Group Inc trades at $67.52 (market cap $7.17B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.5× CAVA Group Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.

CAVAVRTX
Market Cap
$7.17B$132.79B
Sector
Consumer CyclicalHealth
52-Week High
$97.39$529.65
52-Week Low
$43.59$376.62
Enterprise Value
$7.32B$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CAVA Group Inc

CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.

Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CAVA Group Inc

CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.

Read more on CAVA

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX